• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BHC

    Bausch Health Companies Inc.

    Subscribe to $BHC
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

    IPO Year:

    Exchange: NYSE

    Website: bauschhealth.com

    Recent Analyst Ratings for Bausch Health Companies Inc.

    DatePrice TargetRatingAnalyst
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    6/13/2022$12.00Overweight
    JP Morgan
    11/3/2021$41.00 → $40.00Outperform
    RBC Capital
    See more ratings

    Bausch Health Companies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wechsler Amy B was granted 1,062 shares, increasing direct ownership by 0.51% to 209,008 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:36:45 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Icahn Brett was granted 5,119 shares, increasing direct ownership by 3% to 161,899 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:35:23 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Paulson John was granted 9,659 shares, increasing direct ownership by 4% to 277,708 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:34:05 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Controller & CAO Barresi John S covered exercise/tax liability with 7,961 shares, decreasing direct ownership by 4% to 192,268 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      3/3/25 4:08:20 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Appio Thomas covered exercise/tax liability with 206,849 shares, decreasing direct ownership by 10% to 1,783,249 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      3/3/25 4:07:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, General Counsel Carson Seana covered exercise/tax liability with 49,292 shares, decreasing direct ownership by 8% to 564,292 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      3/3/25 4:05:19 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Controller & CAO Barresi John S was granted 49,823 shares, increasing direct ownership by 33% to 200,229 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      2/28/25 4:45:03 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, US Pharma Lenar Aimee J. was granted 108,311 shares, increasing direct ownership by 75% to 252,663 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      2/28/25 4:44:02 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, General Counsel Carson Seana was granted 180,518 shares, increasing direct ownership by 42% to 613,584 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      2/28/25 4:42:43 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CFO Charhon Jean-Jacques was granted 216,622 shares, increasing direct ownership by 72% to 515,460 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      2/28/25 4:41:09 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Bausch Health Companies Inc. SEC Filings

    See more
    • Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      4/30/25 4:11:13 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bausch Health Companies Inc.

      DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/22/25 7:00:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form CERT filed by Bausch Health Companies Inc.

      CERT - Bausch Health Companies Inc. (0000885590) (Filer)

      4/17/25 9:29:12 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Bausch Health Companies Inc.

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      4/15/25 7:38:43 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-A12B filed by Bausch Health Companies Inc.

      8-A12B - Bausch Health Companies Inc. (0000885590) (Filer)

      4/15/25 6:04:01 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bausch Health Companies Inc.

      DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/2/25 4:06:57 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Bausch Health Companies Inc.

      DEF 14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/2/25 4:05:58 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Companies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      3/25/25 2:40:59 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Companies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      3/19/25 11:57:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      2/19/25 4:25:24 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Bausch Health Companies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bausch Health downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

      8/2/24 7:25:50 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Bausch Health with a new price target

      Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

      7/10/24 8:35:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health upgraded by Jefferies with a new price target

      Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously

      9/20/23 7:27:08 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health downgraded by TD Cowen

      TD Cowen downgraded Bausch Health from Outperform to Market Perform

      6/16/23 7:33:15 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health downgraded by Truist

      Truist downgraded Bausch Health from Buy to Hold

      7/29/22 7:06:07 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Bausch Health from Outperform to Sector Perform and set a new price target of $5.00 from $12.00 previously

      7/29/22 7:05:36 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health downgraded by JP Morgan

      JP Morgan downgraded Bausch Health from Overweight to Neutral

      7/28/22 12:06:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on Bausch Health with a new price target

      JP Morgan resumed coverage of Bausch Health with a rating of Overweight and set a new price target of $12.00

      6/13/22 7:15:38 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Bausch Health Companies with a new price target

      RBC Capital reiterated coverage of Bausch Health Companies with a rating of Outperform and set a new price target of $40.00 from $41.00 previously

      11/3/21 7:09:55 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Bausch Health from Neutral to Underperform and set a new price target of $27.00

      3/24/21 6:25:16 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Bausch Health Companies Inc. Leadership Updates

    Live Leadership Updates

    See more

    Bausch Health Companies Inc. Financials

    Live finance-specific insights

    See more
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Welcomes Two New Members to the Executive Leadership Team

      LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

      7/19/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

      BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

      12/5/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

      Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum DiseaseCollaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex RodriguezLAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community.Gum disease, also known as periodont

      9/21/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kimball Electronics, Inc. Announces Appointment of Additional Director

      Kimball Electronics, Inc. (NASDAQ:KE), announces the expansion of its Board of Directors and appointment of a new director at its regularly scheduled Board Meeting on September 13, 2022. Tom Vadaketh was selected to the Company's Board of Directors (the "Board"), effective as of the September meeting. Mr. Vadaketh will serve on the Audit Committee and will stand for election to a full term at the 2022 Annual Meeting of Share Owners in November. Mr. Vadaketh serves as Chief Financial Officer of Bausch Health (NYSE:BHC) (TSX:BHC), which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices globally, primarily in the therapeutic areas of eye-heal

      9/15/22 4:05:00 PM ET
      $BHC
      $KE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Electrical Products
      Technology
    • OcuTerra Strengthens Board of Directors with Three New Key Appointments

      Biotech Leader Brent Saunders Named Chairman of Board Robert Ruffolo, Ph.D, and Robin Steele Named Board Members OcuTerra Therapeutics, Inc. ("OcuTerra"), a clinical stage ophthalmology drug development company focused on treating diabetic retinopathy earlier to preserve vision and avoid intravitreal injections, today announced the appointment of Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors. Brent Saunders will serve as Chairman and William H. Koster, Ph.D, will remain on the Board as Vice Chair. "The appointment of Brent as our Chairman and the addition of Bob and Robin to our Board underscores the momentum and growth of OcuTerra. A recognized biotec

      5/5/21 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Second Quarter 2024 Results

      Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth

      7/31/24 12:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

      LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, August 1, 2024Time:8:00 a.m. U.S. ESTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please

      7/11/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces First Quarter 2024 Results

      First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13%Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + LombReaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financia

      5/2/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce First-Quarter 2024 Results on May 2

      LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, May 2, 2024Time:8:00 a.m. U.S. EDTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please regis

      4/11/24 4:22:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22

      LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, Feb. 22, 2024Time:8:00 a.m. U.S. ESTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, p

      2/1/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2

      LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, Nov. 2, 2023Time:8:00 a.m. U.S. EDTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please re

      10/12/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3

      LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, Aug. 3, 2023Time:8:00 a.m. U.S. EDTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please register using

      7/13/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce First-Quarter 2023 Results on May 4

      LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, May 4, 2023Time:8:00 a.m. U.S. EDTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please regist

      4/13/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Bausch Health Companies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

      LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc

      1/17/25 9:25:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

      LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is

      12/12/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

      LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t

      12/5/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

      LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older,1 has received positive reimbursement recommendations from Canada's Drug Agency (CDA, formerly the Canadian Agency for Drugs and Technology in Health) and Quebec's Institut national d'excellence en santé et en services sociaux (INESSS).The recommendations are an important element in the process to achieve reimbursement of a new medic

      11/18/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

      Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Association for the Study of Liver Disease (AASLD), The Liver Meeting® in San Diego, CA. This clinical program was designed to assess the efficacy of a next generation therapeutic, a soluble solid dispersion (SSD) immediate-release rifaximin product, to delay onset of first overt hepatic encephalopathy (OHE

      11/18/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

      Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) re

      10/27/24 12:15:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

      Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.,

      10/8/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Bausch Health Companies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      8/30/24 6:12:52 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      8/19/24 5:48:41 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/24 4:30:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/7/24 9:00:18 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/23 4:11:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      12/13/21 5:00:16 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      6/21/21 4:44:22 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      4/23/21 5:16:55 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      3/16/21 5:00:21 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      3/11/21 5:15:16 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care